We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

5 hedge funds and large institutions have $498K invested in ABVC BioPharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

25% more funds holding

Funds holding: 4 → 5 (+1)

0.33% more ownership

Funds ownership: 0.15% → 0.48% (+0.33%)

57% less capital invested

Capital invested by funds: $1.17M → $498K (-$669K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.21M
2
BlackRock
BlackRock
New York
+$78.9K
3
TRCT
Tower Research Capital (TRC)
New York
+$12.1K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$4K
2
UBS Group
UBS Group
Switzerland
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$398K – – –
Geode Capital Management
2
Geode Capital Management
Massachusetts
$52K – – –
BlackRock
3
BlackRock
New York
$41K +$78.9K +3,904 New
TRCT
4
Tower Research Capital (TRC)
New York
$6K +$12.1K +600 New
AC
5
Armistice Capital
New York
$1.16K +$2.21M +109,275 New
Morgan Stanley
6
Morgan Stanley
New York
– -$4K -146 Closed
UBS Group
7
UBS Group
Switzerland
– -$3K -127 Closed

ABVC Hedge Fund Activity: Q2 2022 in Review

5 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2022, worth a combined $498K — down 57% from $1.17M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ABVC positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $2.21M. The largest seller was Morgan Stanley, exiting entirely with an estimated $4K sold.

  • 5 institutional investors held ABVC BioPharma (ABVC) as of Q2 2022, up from 4 in Q1 2022.
  • Funds reported $498K of ABVC BioPharma stock for Q2 2022, down 57% quarter-over-quarter.
  • 3 funds opened new ABVC BioPharma positions in Q2 2022 and 2 closed out, a net change of +1 holder.
  • The largest ABVC BioPharma buyer in Q2 2022 was Armistice Capital, an estimated $2.21M added.
  • The largest ABVC BioPharma seller in Q2 2022 was Morgan Stanley, an estimated $4K sold.

Based on aggregated 13F filings for Q2 2022.